Cited by 669Virus-based gene therapy researchImmunotherapy and Immune ResponsesSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 132 of the 134 references it cites were found in a registry or an index.

Adenoviruses as vaccine vectors

Open access

Tatsis, Nia, Ertl, Hildegund C.J.·2004·Molecular Therapy

DOI 10.1016/j.ymthe.2004.07.013PMC PMC7106330

Open this paper in CoChat — free account

Abstract

Adenoviruses have transitioned from tools for gene replacement therapy to bona fide vaccine delivery vehicles. They are attractive vaccine vectors as they induce both innate and adaptive immune responses in mammalian hosts. Currently, adenovirus vectors are being tested as subunit vaccine systems for numerous infectious agents ranging from malaria to HIV-1. Additionally, they are being explored as vaccines against a multitude of tumor-associated antigens. In this review we describe the molecular biology of adenoviruses as well as ways the adenovirus vectors can be manipulated to enhance their efficacy as vaccine carriers. We describe methods of evaluating immune responses to transgene products expressed by adenoviral vectors and discuss data on adenoviral vaccines to a selected number of pathogens. Last, we comment on the limitations of using human adenoviral vectors and provide alternatives to circumvent these problems. This field is growing at an exciting and rapid pace, thus we have limited our scope to the use of adenoviral vectors as vaccines against viral pathogens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2004.07.013

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“3 , are now available [61] [62] [63] [64] .”
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt‐Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Innate immune recognition: mechanisms and pathways
Medzhitov, R., & Janeway, C. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.917309.x · Cited by 1,589
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
Shiver, J. W., Fu, T., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,173
Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
Yang, Y., Li, Q., Ertl, H. C. J., & Wilson, J. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2004-2015.1995 · Cited by 1,033
Self-citation
A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
TSANG, K. W. T., Ho, P., OOI, G. C., Yee, W. K. S., Wang, T., Chan-Yeung, M. M. W., Lam, W. K., Seto, W., Yam, L. Y.-C., CHEUNG, T. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030666 · Cited by 1,018
CD46 is a cellular receptor for group B adenoviruses
Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003) · Nature Medicine · doi:10.1038/nm952 · Cited by 793
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 655

Flagged first, then by citations

Show all 134 references

2 of the 134 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Fisher, 2000, Protection and retargeting of adenovirus using a multifunctional hydrophilic polymer, Mol. Ther., 1S, 57

Sorted by citations

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
Darrah, P. A., Patel, D. T., Luca, P. M. D., Lindsay, R. W. B., Davey, D. F., Flynn, B. J., Hoff, S. T., Andersen, P. L., Reed, S. G., Morris, S. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1592 · Cited by 1,364
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055
Viral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
SARS-CoV-2 Vaccines
Creech, C. B., Walker, S. C., & Samuels, R. J. (2021) · JAMA · doi:10.1001/jama.2021.3199 · Cited by 428
Current state and challenges in developing oral vaccines
Ramirez, J. E. V., Sharpe, L. A., & Peppas, N. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.008 · Cited by 425
Atomic Structure of Human Adenovirus by Cryo-EM Reveals Interactions Among Protein Networks
Liu, H., Jin, L., Koh, S. B. S., Atanasov, I. C., Schein, S., Wu, L., & Zhou, Z. H. (2010) · Science · doi:10.1126/science.1187433 · Cited by 384
A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity
Dicks, M. D. J., Spencer, A. J., Edwards, N. J., Wadell, G., Bojang, K., Gilbert, S. C., Hill, A. V. S., & Cottingham, M. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040385 · Cited by 384
Innate Immune Response to Adenoviral Vectors Is Mediated by both Toll-Like Receptor-Dependent and -Independent Pathways
Zhu, J., Huang, X., & Yang, Y. (2007) · Journal of Virology · doi:10.1128/jvi.02192-06 · Cited by 370
Recombinant vaccines and the development of new vaccine strategies
Nascimento, I. P., & Leite, L. C. C. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2012007500142 · Cited by 368
Viruses as vaccine vectors for infectious diseases and cancer
Draper, S. J., & Heeney, J. L. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2240 · Cited by 358
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees
Folgori, A., Capone, S., Ruggeri, L., Meola, A., Sporeno, E., Ercole, B. B., Pezzanera, M., Tafi, R., Arcuri, M., Fattori, E., et al. (2006) · Nature Medicine · doi:10.1038/nm1353 · Cited by 322
The use of viral vectors in vaccine development
Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. (2022) · npj Vaccines · doi:10.1038/s41541-022-00503-y · Cited by 316
Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species
Colloca, S., Barnes, E. J., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., Esposito, M. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002925 · Cited by 299
Pre-existing immunity against Ad vectors
Fausther‐Bovendo, H., & Kobinger, G. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29594 · Cited by 285
Viral Delivery Systems for CRISPR
Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (2019) · Viruses · doi:10.3390/v11010028 · Cited by 277
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
Mast, T. C., Kierstead, L. S., Gupta, S. B., Nikas, A. A., Kallas, E. G., Novitsky, V., Mbewe, B., Pitisuttithum, P., Schechter, M., Vardas, E., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.145 · Cited by 283
Viral vector‐based gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269
New Insights on Adenovirus as Vaccine Vectors
Lasaro, M. O., & Ertl, H. C. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.130 · Cited by 263
Self-citation
Adenovirus Receptors
Zhang, Y., & Bergelson, J. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.19.12125-12131.2005 · Cited by 262
Modification of Adenovirus Gene Transfer Vectors With Synthetic Polymers: A Scientific Review and Technical Guide
Kreppel, F., & Kochanek, S. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300321 · Cited by 239
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
O’Hara, G. A., Duncan, C. J. A., Ewer, K., Collins, K. A., Elias, S. C., Halstead, F. D., Goodman, A. L., Edwards, N. J., Reyes‐Sandoval, A., Bird, P., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir850 · Cited by 214
Engineered lentivector targeting of dendritic cells for in vivo immunization
Yang, L., Yang, H., Rideout, K., Cho, T., Joo, K. I., Ziegler, L., Elliot, A. M., Walls, A., Yu, D., Baltimore, D., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1390 · Cited by 208
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
Heppner, D. G., Kester, K. E., Ockenhouse, C. F., Tornieporth, N., Ofori, O., Lyon, J. A., Stewart, V. A., Dubois, P. M., Lanar, D. E., & Krzych, U. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.142 · Cited by 193
Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. H. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 208
Replication-defective viruses as vaccines and vaccine vectors
Dudek, T., & Knipe, D. M. (2005) · Virology · doi:10.1016/j.virol.2005.09.020 · Cited by 189
Progress and Challenges toward the Development of Vaccines against Avian Infectious Bronchitis
Bande, F., Arshad, S. S., Bejo, M. H., Moeini, H., & Omar, A. R. (2015) · Journal of Immunology Research · doi:10.1155/2015/424860 · Cited by 175
Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass
Alcock, R. S., Cottingham, M. G., Rollier, C. S., Furze, J. M., Costa, S. D. D., Hanlon, M., Spencer, A. J., Honeycutt, J. D., Wyllie, D. H., Gilbert, S. C., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000490 · Cited by 160
Intervertebral disc degeneration—Current therapeutic options and challenges
Samanta, A., Lufkin, T., & Kraus, P. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1156749 · Cited by 168
Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting
Khare, R., Chen, C. Y., Weaver, E. A., & Barry, M. A. (2011) · Current Gene Therapy · doi:10.2174/156652311796150363 · Cited by 156
Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus
Bukreyev, A. A., Rollin, P. E., Tate, M., Yang, L., Zaki, S. R., Shieh, W., Murphy, B. R., Collins, P. L., & Sanchez, A. (2007) · Journal of Virology · doi:10.1128/jvi.00105-07 · Cited by 155
Peste des Petits Ruminants Virus
Baron, M. D., Diallo, A., Lancelot, R., & Libeau, G. (2016) · Advances in virus research · doi:10.1016/bs.aivir.2016.02.001 · Cited by 153
Novel viral vectors in infectious diseases
Humphreys, I. R., & Sebastian, S. (2017) · Immunology · doi:10.1111/imm.12829 · Cited by 145
Development of nonhuman adenoviruses as vaccine vectors
Bangari, D. S., & Mittal, S. K. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.101 · Cited by 142
Improved virus purification processes for vaccines and gene therapy
Nestola, P., Peixoto, C., Silva, R. J. S., Alves, P. M., Mota, J. P. B., & Carrondo, M. J. T. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25545 · Cited by 132
Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
Coughlan, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00909 · Cited by 133
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
Rijkers, G. T., Weterings, N., Obregón‐Henao, A., Dutt, T., Dutt, T. S., van Overveld, F. J., & Henao-Tamayo, M. I. (2021) · Vaccines · doi:10.3390/vaccines9080848 · Cited by 139
Adenovirus Vectors: Excellent Tools for Vaccine Development
Chang, J. (2021) · Immune Network · doi:10.4110/in.2021.21.e6 · Cited by 129
Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months
Pelliccia, M., Andreozzi, P., Paulose, J., D’Alicarnasso, M., Cagno, V., Donalisio, M., Civra, A., Broeckel, R. M., Haese, N. N., Silva, P. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13520 · Cited by 123
Macropinocytotic Uptake and Infection of Human Epithelial Cells with Species B2 Adenovirus Type 35
Kälin, S., Amstutz, B., Gastaldelli, M., Wolfrum, N., Boucke, K., Havenga, M. J. E., DiGennaro, F., Liska, N., Hemmi, S., & Greber, U. F. (2010) · Journal of Virology · doi:10.1128/jvi.02494-09 · Cited by 126
Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses
Price, G. E., Soboleski, M. R., Lo, C.-Y., Misplon, J. A., Quirion, M. R., Houser, K. V., Pearce, M. B., Pappas, C., Tumpey, T. M., & Epstein, S. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013162 · Cited by 121
Mucosal delivery of vaccine antigens and its advantages in pediatrics☆
DEMAGISTRIS, M. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.002 · Cited by 120
Hantavirus entry: Perspectives and recent advances
Mittler, E., Dieterle, M. E., Kleinfelter, L. M., Slough, M. M., Chandran, K., & Jangra, R. K. (2019) · Advances in virus research · doi:10.1016/bs.aivir.2019.07.002 · Cited by 121
Adenoviral vectors
Ghosh, S. S., Gopinath, P., & Ramesh, A. (2006) · Applied Biochemistry and Biotechnology · doi:10.1385/abab:133:1:9 · Cited by 118
Emerging viruses and current strategies for vaccine intervention
Afrough, B., Dowall, S., & Hewson, R. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13295 · Cited by 118
Intranasal Mucosal Boosting with an Adenovirus-Vectored Vaccine Markedly Enhances the Protection of BCG-Primed Guinea Pigs against Pulmonary Tuberculosis
Xing, Z., McFarland, C. T., Sallenave, J., Izzo, A. A., Wang, J., & McMurray, D. N. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005856 · Cited by 114
An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times
Montero, C. G., Fraile‐Μartinez, O., Bravo, C., Torres‐Carranza, D., Sánchez‐Trujillo, L., Gomez-Lahoz, A. M., Guijarro, L. G., García‐Honduvilla, N., Asúnsolo, Á., Buján, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9050433 · Cited by 112
Adenoviral vector-based strategies against infectious disease and cancer
Zhang, C., & Zhou, D. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1165908 · Cited by 110
Tuberculosis vaccines in clinical trials
Rowland, R., & McShane, H. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.28 · Cited by 110
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens
Afkhami, S., Yao, Y., & Xing, Z. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.30 · Cited by 108
Adenovirus Structure
Rux, J. J., & Burnett, R. M. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1167 · Cited by 106
The Immunogenicity of Adenovirus Vectors Limits the Multispecificity of CD8 T-cell Responses to Vector-encoded Transgenic Antigens
Schirmbeck, R., Reimann, J., Kochanek, S., & Kreppel, F. (2008) · Molecular Therapy · doi:10.1038/mt.2008.141 · Cited by 107
Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity toPlasmodium falciparumCS Compared to That with Either Malaria Vaccine Alone
Stewart, V. A., McGrath, S. M., Dubois, P. M., Pau, M. G., Mettens, P., Shott, J. P., Cobb, M., Burge, J. R., LARSON, D. L., Ware, L. A., et al. (2007) · Infection and Immunity · doi:10.1128/iai.01879-06 · Cited by 103
Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9‐dependent maturation and IFN‐α production
Basner‐Tschakarjan, E., Gaffal, E., O’Keeffe, M. A., Tormo, D., Limmer, A., Wagner, H., Hochrein, H., & Tüting, T. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.964 · Cited by 102
Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods
Mashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 102
Nanocarrier vaccines for SARS-CoV-2
Machhi, J., Shahjin, F., Das, S., Patel, M., Abdelmoaty, M. M., Cohen, J. D., Singh, P. A., Baldi, A., Bajwa, N., Kumar, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.002 · Cited by 100
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Pushparajah, D., Jimenez, S., Wong, S. L., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.003 · Cited by 99
Fully Detargeted Polyethylene Glycol-coated Adenovirus Vectors Are Potent Genetic Vaccines and Escape from Pre-existing Anti-adenovirus Antibodies
Wortmann, A., Vöhringer, S., Engler, T., Corjon, S., Schirmbeck, R., Reimann, J., Kochanek, S., & Kreppel, F. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300306 · Cited by 97
Gene therapy for haemophilia
Murphy, S. L., & High, K. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06942.x · Cited by 98
Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy
Ahmadi, S. E., Soleymani, M., Shahriyary, F., Amirzargar, M. R., Mahya, O., Fattahi, D., & Safa, M. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00597-z · Cited by 97
Chimpanzee-origin adenovirus vectors as vaccine carriers
Tatsis, N., Tesema, L., Robinson, E., Giles‐Davis, W., McCoy, K., Gao, G., Wilson, J. M., & Ertl, H. C. J. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302675 · Cited by 93
Self-citation
Novel Vaccines to Human Rabies
Ertl, H. C. J. (2009) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000515 · Cited by 93
Self-citation
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
Morse, M. A., Chaudhry, A., Gabitzsch, E. S., Hobeika, A. C., Osada, T., Clay, T. M., Amalfitano, A., Burnett, B. K., Devi, G. R., Hsu, D. S., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1400-3 · Cited by 97
The CD8+ T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity
Yang, T.-C., Millar, J., Groves, T., Grinshtein, N., Parsons, R., Takenaka, S., Wan, Y., & Bramson, J. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.200 · Cited by 92
Zika vaccines and therapeutics: landscape analysis and challenges ahead
Wilder‐Smith, A., Vannice, K., Durbin, A. P., Hombach, J., Thomas, S. J., Thevarjan, I., & Simmons, C. P. (2018) · BMC Medicine · doi:10.1186/s12916-018-1067-x · Cited by 91
Single‐dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
Reyes‐Sandoval, A., Sridhar, S., Berthoud, T. K., Moore, A., Harty, J. T., Gilbert, S. C., Gao, G., Ertl, H. C. J., Wilson, J. M., & Hill, A. V. S. (2008) · European Journal of Immunology · doi:10.1002/eji.200737672 · Cited by 92
Self-citation
Long-Term Protective Immunity Induced Against Trypanosoma cruzi Infection After Vaccination with Recombinant Adenoviruses Encoding Amastigote Surface Protein-2 and Trans -Sialidase
Machado, A. V., Cardoso, J. E., Claser, C., Rodrigues, M. M., Gazzinelli, R. T., & Bruña–Romero, O. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.898 · Cited by 92
Evading the immune response upon in vivo gene therapy with viral vectors.
Sack, B. K., & Herzog, R. W. (2009) · PubMed · Cited by 92
Adenovirus-vectored novel African Swine Fever Virus antigens elicit robust immune responses in swine
Lokhandwala, S., Waghela, S. D., Bray, J., Sangewar, N., Charendoff, C. I., Martin, C. L., Hassan, W. S., Koynarski, T., Gabbert, L. R., Burrage, T. G., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177007 · Cited by 89
Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 Vectors
Penaloza‐MacMaster, P., Provine, N. M., Ra, J., Borducchi, E. N., McNally, A. G., Simmons, N. L., Iampietro, M. J., & Barouch, D. H. (2012) · Journal of Virology · doi:10.1128/jvi.02058-12 · Cited by 83
Review of COVID-19 viral vector-based vaccines and COVID-19 variants
Vanaparthy, R., Mohan, G., Vasireddy, D., & Atluri, P. (2021) · Infezioni in Medicina · doi:10.53854/liim-2903-3 · Cited by 88
A Critical Role for Type I IFN–dependent NK Cell Activation in Innate Immune Elimination of Adenoviral Vectors In Vivo
Zhu, J., Huang, X., & Yang, Y. (2008) · Molecular Therapy · doi:10.1038/mt.2008.88 · Cited by 89
Replication-Deficient Ebolavirus as a Vaccine Candidate
Halfmann, P., Ebihara, H., Marzi, A., Hatta, Y., Watanabe, S., Suresh, M., Neumann, G., Feldmann, H., & Kawaoka, Y. (2009) · Journal of Virology · doi:10.1128/jvi.00074-09 · Cited by 87
A Novel Adenovirus Type 6 (Ad6)-Based Hepatitis C Virus Vector That Overcomes Preexisting Anti-Ad5 Immunity and Induces Potent and Broad Cellular Immune Responses in Rhesus Macaques
Capone, S., Meola, A., Ercole, B. B., Vitelli, A., Pezzanera, M., Ruggeri, L., Davies, M. E. M., Tafi, R., Santini, C., Luzzago, A., et al. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.1688-1699.2006 · Cited by 86
Gene Therapy for Regenerative Medicine
Hosseinkhani, H., Domb, A. J., Sharifzadeh, G., & Nahum, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030856 · Cited by 89
A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues
Khandker, S. S., Godman, B., Jawad, M. I., Meghla, B. A., Tisha, T. A., Khondoker, M. U., Haq, M. A., Charan, J., Talukder, A. A., Azmuda, N., et al. (2021) · Vaccines · doi:10.3390/vaccines9121387 · Cited by 88
Adenovirus Vectors Expressing Hantavirus Proteins Protect Hamsters against Lethal Challenge with Andes Virus
Safronetz, D., Hegde, N. R., Ebihara, H., Denton, M. C., Kobinger, G., Jeor, S. S., Feldmann, H., & Johnson, D. C. (2009) · Journal of Virology · doi:10.1128/jvi.00373-09 · Cited by 83
Mechanism of Ad5 Vaccine Immunity and Toxicity: Fiber Shaft Targeting of Dendritic Cells
Cheng, C., Gall, J. G. D., Kong, W., Sheets, R., Gomez, P. L., King, C. R., & Nabel, G. J. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030025 · Cited by 83
Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system
Rahimi, H., Salehiabar, M., Charmi, J., Barsbay, M., Ghaffarlou, M., Razlighi, M. R., Davaran, S., Khalilov, R. I., Sugiyama, M., Nosrati, H., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100895 · Cited by 83
Seroprevalence of neutralizing antibodies to human adenoviruses type‐5 and type‐26 and chimpanzee adenovirus type‐68 in healthy Chinese adults
Zhang, S., Huang, W., Zhou, X., Zhao, Q., Wang, Q., & Jia, B. (2013) · Journal of Medical Virology · doi:10.1002/jmv.23546 · Cited by 82
Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions
Delplace, V., Payne, S. L., & Shoichet, M. S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.065 · Cited by 82
COVID-19 Vaccines: An Overview of Different Platforms
Kudlay, D. A., & Svistunov, A. А. (2022) · Bioengineering · doi:10.3390/bioengineering9020072 · Cited by 81
Current view on novel vaccine technologies to combat human infectious diseases
Matić, Z., & Šantak, M. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11713-0 · Cited by 83
Recombinant covalently closed circular DNA of hepatitis B virus induces long‐term viral persistence with chronic hepatitis in a mouse model
Li, G.-Y., Zhu, Y.-F., Shao, D., Chang, H., Zhang, X., Zhou, D., Gao, Y.-Q., Lan, K., & Deng, Q. (2018) · Hepatology · doi:10.1002/hep.29406 · Cited by 71
Advances in Oral Subunit Vaccine Design
der Weken, H. V., Cox, E., & Devriendt, B. (2020) · Vaccines · doi:10.3390/vaccines9010001 · Cited by 82
Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.
Hensley, S. E., Cun, A. S., Giles-Davis, W., Li, Y., Xiang, Z., Lasaro, M. O., Williams, B. R. G., Silverman, R. H., & Ertl, H. C. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300024 · Cited by 78
Self-citation
Bovine Adenoviral Vector–based H5N1 Influenza Vaccine Overcomes Exceptionally High Levels of Pre-existing Immunity Against Human Adenovirus
Singh, N., Pandey, A., Jayashankar, L., & Mittal, S. K. (2008) · Molecular Therapy · doi:10.1038/mt.2008.12 · Cited by 78
Dengue Virus Vaccine Development
Yauch, L. E., & Shresta, S. (2014) · Advances in virus research · doi:10.1016/b978-0-12-800098-4.00007-6 · Cited by 77
Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys
Ersching, J., Hernández, M. I. M., Cezarotto, F. S., Ferreira, J. D. S., Martins, A. B., Switzer, W. M., Xiang, Z., Ertl, H. C. J., Zanetti, C. R., & Pinto, A. R. (2010) · Virology · doi:10.1016/j.virol.2010.07.043 · Cited by 76
Self-citation
Induction of Robust Immune Responses in Swine by Using a Cocktail of Adenovirus-Vectored African Swine Fever Virus Antigens
Lokhandwala, S., Waghela, S. D., Bray, J., Martin, C. L., Sangewar, N., Charendoff, C. I., Shetti, R., Ashley, C., Chen, C.-H., Berghman, L. R., et al. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00395-16 · Cited by 76
iTRAQ-Based and Label-Free Proteomics Approaches for Studies of Human Adenovirus Infections
Trinh, H. V., Grossmann, J., Gehrig, P., Roschitzki, B., Schlapbach, R., Greber, U. F., & Hemmi, S. (2013) · International Journal of Proteomics · doi:10.1155/2013/581862 · Cited by 72
Dendritic Cell Maturation, but Not CD8+ T Cell Induction, Is Dependent on Type I IFN Signaling during Vaccination with Adenovirus Vectors
Hensley, S. E., Giles‐Davis, W., McCoy, K. C., Weninger, W., & Ertl, H. C. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6032 · Cited by 73
Self-citation
Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles
Srivastava, A. K., Gowda, D. V., Madhunapantula, S. V., Shinde, C. G., & Meenakshi, S. S. (2015) · Apmis · doi:10.1111/apm.12351 · Cited by 75
Vaccination strategies against Zika virus
Fernández, E., & Diamond, M. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.03.006 · Cited by 75
Vaccination against tuberculosis: How can we better BCG?
Pitt, J. M., Blankley, S., McShane, H., & O’Garra, A. (2012) · Microbial Pathogenesis · doi:10.1016/j.micpath.2012.12.002 · Cited by 73
Evaluation of OX40 Ligand as a Costimulator of Human Antiviral Memory CD8 T Cell Responses: Comparison with B7.1 and 4-1BBL
Serghides, L., Bukczynski, J., Wen, T., Wang, C., Routy, J., Boulassel, M., Sékaly, R., Ostrowski, M., Bernard, N. F., & Watts, T. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.6368 · Cited by 72
Comparison of Vaccine-Induced Effector CD8 T Cell Responses Directed against Self- and Non–Self-Tumor Antigens: Implications for Cancer Immunotherapy
Pedersen, S. R., Sørensen, M. R., Buus, S., Christensen, J. P., & Thomsen, A. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300555 · Cited by 76
Development of replication-competent viral vectors for HIV vaccine delivery
Parks, C. L., Picker, L. J., & King, C. R. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328363d389 · Cited by 71
Oral Vaccines: A Better Future of Immunization
Kwong, K. W.-Y., Xin, Y., Lai, N. C.-Y., Sung, J. C.-C., Wu, K.-C., Hamied, Y. K., Sze, E. T.-P., & Lam, D. M. (2023) · Vaccines · doi:10.3390/vaccines11071232 · Cited by 79
Antigen delivery systems for veterinary vaccine development
Brun, A., Albina, E., Barret, T., Chapman, D. A., Czub, M., Dixon, L. K., Keil, G. M., Klonjkowski, B., Potier, M. L., Libeau, G., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.044 · Cited by 71

Authors: Tatsis, N., & Ertl, H. C. J.
Affiliations: The Wistar Institute (US)
Corresponding author: Ertl, Hildegund C.J.
ORCID: Ertl, Hildegund C.J.
Venue: Molecular Therapy
Publisher: Elsevier BV
Published: 2004-10
Volume: 10
Issue: 4
Pages: 616-629
ISSN: 1525-0016 (ISSN-L)
DOI: 10.1016/j.ymthe.2004.07.013
PMC: PMC7106330
OpenAlex: W1972258033
Cited by: 669
References: 134
Citations by year: 2026: 16 · 2025: 28 · 2024: 31 · 2023: 60 · 2022: 58 · 2021: 69 · 2020: 26 · 2019: 25 · 2018: 19 · 2017: 20 · 2016: 26 · 2015: 24 · 2014: 21 · 2013: 28 · 2012: 23
FWCI: 3.15
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 4389 d)
Locations: Molecular Therapy (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: adenoviral vector, vaccine vectors, subunit vaccine, viral vaccines, innate immune response, adaptive immune response, transgene expression, HIV-1 vaccine, malaria vaccine, tumor-associated antigens
MeSH terms: Adenoviridae, Adenoviridae Infections, Genes, Viral, Genetic Vectors, Humans, Peptides, Viral Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adenoviruses as vaccine vectors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks